<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04723472</url>
  </required_header>
  <id_info>
    <org_study_id>2020/041</org_study_id>
    <nct_id>NCT04723472</nct_id>
  </id_info>
  <brief_title>Bismuth Quadruple Therapy With Cefuroxime for Helicobacter Pylori Eradication Treatment</brief_title>
  <official_title>An Open Randomized Controlled Study of Bismuth Quadruple Therapy With Cefuroxime as Rescue Therapy for Helicobacter Pylori Infection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shanghai East Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shanghai East Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To observe the efficacy of cefuroxime-containing bismuth quadruple regimen in the eradication&#xD;
      treatment of Helicobacter pylori, and to evaluate whether it can be used as a remedial&#xD;
      treatment for Helicobacter pylori after initial or repeated treatment failure.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Introducing cefuroxime into the remedy treatment of Helicobacter pylori, on the one hand, the&#xD;
      investigators will observe whether cefuroxime can replace tetracycline like amoxicillin, on&#xD;
      the other hand, the investigators will observe whether it can reduce the rate of adverse&#xD;
      effects caused by tetracycline and avoid the allergy of penicillin. If the experiment is&#xD;
      successful, it will provide an effective and safe second-line treatment for the majority of&#xD;
      patients with failed treatment of Helicobacter pylori.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">October 1, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Comparison of success rates after 14 days of eradicate treatment with helicobacter pylori using a bismuth quadruple regimen containing cefuroxime and a classic bismuth quadruple regimen</measure>
    <time_frame>The duration of treatment is 14 days. A C13 UBT will be performed 1 month after treatment.</time_frame>
    <description>The comparison of eradication rate (0-100%), it is better to have a higher eradication rate.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The Success rate of cefuroxime-containing bismuth quadruple regimen in the treatment of refractory Helicobacter pylori after 14 days</measure>
    <time_frame>A C13 UBT will be performed 1 month after treatment.</time_frame>
    <description>The eradication rate of new regimen in refractory Helicobacter pylori treatment (0-100%)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>In vitro culture and drug sensitivity test of Helicobacter pylori were conducted to observe the drug resistance rate of Helicobacter pylori to cefuroxime, tetracycline and metronidazole.</measure>
    <time_frame>before the treatment</time_frame>
    <description>The drug resistance rate of Helicobacter pylori to cefuroxime, tetracycline and metronidazole（0-100%）</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse effect rate and safety of cefuroxime-containing bismuth quadruple regimen and classical bismuth quadruple regimen in patients with refractory Helicobacter pylori.</measure>
    <time_frame>one month after treatment.</time_frame>
    <description>questionnaire ; follow-up visit</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">82</enrollment>
  <condition>Helicobacter Pylori Infection</condition>
  <arm_group>
    <arm_group_label>Classic bismuth quadruple treatment group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Cefuroxime containing bismuth quadruple treatment group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cefuroxime containing bismuth quadruple treatment</intervention_name>
    <description>Cefuroxime containing bismuth quadruple treatment:&#xD;
Rabeprazole 20mg bid po, Colloidal Bismuth Pectin 200mg bid po, Cefuroxime 500mg bid po, Metronidazole 400mg tid po Treatment duration is 14 days.</description>
    <arm_group_label>Cefuroxime containing bismuth quadruple treatment group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Classic bismuth quadruple treatment</intervention_name>
    <description>Classic bismuth quadruple treatment:&#xD;
Rabeprazole 20mg bid po, Colloidal Bismuth Pectin 200mg bid po, Tetracycline 500mg qid po, Metronidazole 400mg tid po Treatment duration is 14 days.</description>
    <arm_group_label>Classic bismuth quadruple treatment group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Employees, family members, and patients with positive C13 breath test in our hospital;&#xD;
&#xD;
          -  Has received one or more previous Helicobacter pylori eradication therapy (no use of&#xD;
             cefuroxime or tetracycline), and the result is still positive by C13 breath test;&#xD;
&#xD;
          -  Willing to undergo gastroscopy and HP cultivation and identification;&#xD;
&#xD;
          -  Age 18-70, gender unlimited;&#xD;
&#xD;
          -  Willing to participate in and cooperate with the study, and willing to sign the&#xD;
             informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Drugs that may affect the study results, such as PPI, H2 blockers, bismuth agents,&#xD;
             antibiotics, etc. were taken in the 4 weeks before enrollment;&#xD;
&#xD;
          -  Patients with gastrointestinal malignancy tumor;&#xD;
&#xD;
          -  Patients with gastrinoma;&#xD;
&#xD;
          -  After gastric or esophageal surgery;&#xD;
&#xD;
          -  Suffers from serious diseases of the heart, lung, kidney, liver, blood, nervous&#xD;
             system, endocrine system or mental system;&#xD;
&#xD;
          -  Patients with contraindications or previous allergic reactions to the drugs used in&#xD;
             this study;&#xD;
&#xD;
          -  Pregnant or breastfeeding women;&#xD;
&#xD;
          -  Patients with other medical conditions that may increase the treatment side effects;&#xD;
&#xD;
          -  Those who cannot give informed consent;&#xD;
&#xD;
          -  Has participated in other drug trials within 3 months;&#xD;
&#xD;
          -  Not considered suitable for participants by the investigator.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Meidong Xu</last_name>
    <role>Study Director</role>
    <affiliation>ShanghaiDongfang Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Xinyan Zhu</last_name>
    <phone>862138804518</phone>
    <phone_ext>12072</phone_ext>
    <email>xinyan.zhu@tongji.edu.cn</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Fei Xu</last_name>
    <phone>862138804518</phone>
    <phone_ext>12072</phone_ext>
    <email>sophiayouyou@sina.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Shanghai East Hospital</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200120</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>January 21, 2021</study_first_submitted>
  <study_first_submitted_qc>January 21, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 25, 2021</study_first_posted>
  <last_update_submitted>September 23, 2021</last_update_submitted>
  <last_update_submitted_qc>September 23, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 27, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infections</mesh_term>
    <mesh_term>Helicobacter Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cefuroxime</mesh_term>
    <mesh_term>Cefuroxime axetil</mesh_term>
    <mesh_term>Bismuth</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Guildline in patient consent form</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

